RespireRx Pharmaceuticals Inc (fka RSPI)

[bladerunner1717]

Jerry,

I don't see why this has to be so complicated, i.e. bringing in an equity partner at this stage. A partnership could be done for CX1739 with enough upfronts to get through a Phase II in ADHD, then the partner takes over for further trials, if Phase II proves successful. This happens all the time.

I don't see why you are so insistent on an equity partner here, when CORX now has a molecule, 1739, that they can outlicense that has potential efficacy in SA, schizo, depression, RD and ADHD.


Bladerunner